VITA 34 AG
VITA 34 AG engages in the collection, processing, and storage of stem cells from umbilical cord blood and tissue in Germany, Spain, and internationally. It also develops cell therapeutic procedures; cell and gene therapies; cryopreservation of endogenous…
Medical - Care Facilities
DE, Leipzig [HQ]
FA
Fundamental Analysis · Most Recent Quarter
A dedicated fundamental analysis might help you to get a quick overview
of the
financial stability. It is important to understand the
FA Algorithm
and the criterias before valuing it as a top-tier resource.
1
Financial Health
| Metric | Q4 | Q1 | Δ in % | |
|---|---|---|---|---|
| Current Ratio | -3.21 | 0.71 | 0.73 | |
| Debt/Assets | n.A. | n.A. | n.A. | |
| Debt/Equity | n.A. | n.A. | n.A. | |
| Net Debt/EBITDA | -13.59 | 2.51 | 2.90 | |
| Naive Interpretation | member | |||
2
Per Share
| Metric | Q4 | Q1 | Δ in % | |
|---|---|---|---|---|
| Book Value | -1.18 | 1.34 | 1.35 | |
| Cash | -20.59 | 0.87 | 1.09 | |
| Capex | -86.56 | -0.07 | -0.04 | |
| Free Cash Flow | -15.79 | 0.16 | 0.18 | |
| Revenue | -8.95 | 1.06 | 1.17 | |
| Naive Interpretation | member | |||
3
Profitability
| Metric | Q4 | Q1 | Δ in % | |
|---|---|---|---|---|
| Gross Margin | 11.10 | 0.38 | 0.34 | |
| Operating Margin | -55.01 | -0.05 | -0.04 | |
| ROA | -78.36 | < 0.005 | 0.02 | |
| ROE | -78.46 | -0.03 | 0.16 | |
| ROIC | 66.54 | -0.02 | -0.06 | |
| Naive Interpretation | member | |||
4
Valuation
The "Valuation Entry" for the Focus of V3V.DE is permitted for members.
5
Growth
The "Growth Entry" for the Focus of V3V.DE is permitted for members.
6
Leverage & Liquidity